MX2021000732A - Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo para tratar ham. - Google Patents

Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo para tratar ham.

Info

Publication number
MX2021000732A
MX2021000732A MX2021000732A MX2021000732A MX2021000732A MX 2021000732 A MX2021000732 A MX 2021000732A MX 2021000732 A MX2021000732 A MX 2021000732A MX 2021000732 A MX2021000732 A MX 2021000732A MX 2021000732 A MX2021000732 A MX 2021000732A
Authority
MX
Mexico
Prior art keywords
ham
treatment
agent
htlv
prevention
Prior art date
Application number
MX2021000732A
Other languages
English (en)
Inventor
Yoshihisa Yamano
Kaoru Uchimaru
Makoto Yamagishi
Izumi Ishizaki
Original Assignee
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokyo filed Critical Univ Tokyo
Publication of MX2021000732A publication Critical patent/MX2021000732A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un agente terapéutico o profiláctico para la mielopatía asociada al HTLV-1 (HAM), que comprende una sustancia inhibidora de la RGMa y un método para tratar la mielopatía asociada al HTLV-1 (HAM), que comprende la administración de una cantidad farmacológicamente eficaz de una sustancia inhibidora de la RGMa a un paciente con HAM que la necesite.
MX2021000732A 2018-07-19 2019-07-19 Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo para tratar ham. MX2021000732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018135925 2018-07-19
PCT/JP2019/028431 WO2020017629A1 (ja) 2018-07-19 2019-07-19 Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法

Publications (1)

Publication Number Publication Date
MX2021000732A true MX2021000732A (es) 2021-04-28

Family

ID=69163691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000732A MX2021000732A (es) 2018-07-19 2019-07-19 Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo para tratar ham.

Country Status (16)

Country Link
US (1) US20210269535A1 (es)
EP (1) EP3824907A4 (es)
JP (2) JP7150286B2 (es)
KR (1) KR20210034055A (es)
CN (4) CN112566664B (es)
AU (1) AU2019306721A1 (es)
BR (1) BR112021000949A2 (es)
CA (1) CA3112511A1 (es)
IL (1) IL280257A (es)
MX (1) MX2021000732A (es)
PE (1) PE20211376A1 (es)
PH (1) PH12021550134A1 (es)
SG (1) SG11202100561QA (es)
TW (1) TWI825131B (es)
WO (1) WO2020017629A1 (es)
ZA (1) ZA202101113B (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
KR20070015398A (ko) * 2004-03-11 2007-02-02 바이오클루즈 가부시키가이샤 축색 재생 촉진제
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
KR101635489B1 (ko) 2008-09-02 2016-07-01 도레이 배터리 세퍼레이터 필름 주식회사 미세다공성 고분자막, 이 미세다공성 고분자막의 제조방법 및 전지 세퍼레이터 필름으로서의 이 미세다공성 고분자막의 사용
JP5552630B2 (ja) 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法
KR102223464B1 (ko) 2009-12-09 2021-03-05 미쓰비시 타나베 파마 코퍼레이션 Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
ES2778053T3 (es) * 2011-01-18 2020-08-07 Bioniz Llc Composiciones para modular la actividad de la citocina gamma-c
JP5963233B2 (ja) * 2011-12-07 2016-08-03 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−１関連脊髄症を治療または予防するための医薬および前記医薬を用いた抗体療法の治療効果の確認方法
WO2014007303A1 (ja) * 2012-07-06 2014-01-09 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ－１関連脊髄症患者の治療方法および治療剤
EP3191847A1 (en) 2014-09-10 2017-07-19 AbbVie Deutschland GmbH & Co. KG Rgma fragment based diagnostic assay
SG11201708848TA (en) * 2015-04-28 2017-11-29 Mitsubishi Tanabe Pharma Corp RGMa BINDING PROTEIN AND USE THEREOF
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
BR112018074966A2 (pt) * 2016-06-01 2019-03-12 AbbVie Deutschland GmbH & Co. KG anticorpos antagonísticos anti-molécula de orientação repulsiva a (grma) para tratar lesão na medula espinhal e dor
JP6923215B2 (ja) * 2016-08-03 2021-08-18 国立大学法人 鹿児島大学 抗ｈｔｌｖ−１剤、ｈｔｌｖ−１関連脊髄症（ｈａｍ／ｔｓｐ）治療薬

Also Published As

Publication number Publication date
EP3824907A1 (en) 2021-05-26
WO2020017629A1 (ja) 2020-01-23
BR112021000949A2 (pt) 2021-04-27
PE20211376A1 (es) 2021-07-27
JP2022180487A (ja) 2022-12-06
CA3112511A1 (en) 2020-01-23
JPWO2020017629A1 (ja) 2021-08-02
EP3824907A4 (en) 2022-05-04
SG11202100561QA (en) 2021-02-25
JP7475011B2 (ja) 2024-04-26
US20210269535A1 (en) 2021-09-02
IL280257A (en) 2021-03-25
CN112566664A (zh) 2021-03-26
PH12021550134A1 (en) 2021-09-27
TW202019482A (zh) 2020-06-01
CN116850291A (zh) 2023-10-10
ZA202101113B (en) 2022-07-27
CN116942831A (zh) 2023-10-27
JP7150286B2 (ja) 2022-10-11
CN116785439A (zh) 2023-09-22
AU2019306721A1 (en) 2021-03-11
TWI825131B (zh) 2023-12-11
KR20210034055A (ko) 2021-03-29
CN112566664B (zh) 2023-08-25

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
JOP20200122A1 (ar) مركبات مفيدة لتثبيط cdk7
PH12016502355A1 (en) Pharmaceutical composition
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
CR20190531A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
CR20190530A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
EA201800499A1 (ru) Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
MX2021005944A (es) Inhibidores de rip1.
PH12020550031A1 (en) Composition for use in the prevention and treatment of pathologies of the cardiovascular apparatus
MX2023006651A (es) Tratamiento de la hemofilia con fitusirán.
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2019002149A (es) Metodo para el tratamiento de prurito y/o comezon.
MX2023002482A (es) Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
MX2021000732A (es) Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo para tratar ham.
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
MX2022008532A (es) Inhibidores de hidrocarburo de arilo (ahr) y usos de estos.